Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y DirixIstvan TakacsGuy JerusalemPetros NikolinakosHendrik-Tobias ArkenauAndres Forero-TorresRalph BocciaMarc E LippmanRobert SomerMartin SmakalLeisha A EmensBorys HrinczenkoWilliam EdenfieldJayne GurtlerAnja von HeydebreckHans Juergen GroteKevin ChinErika P HamiltonPublished in: Breast cancer research and treatment (2017)
Avelumab showed an acceptable safety profile and clinical activity in a subset of patients with MBC. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC.